teleo-codex/inbox/archive/2025-02-03-usc-schaeffer-upcoding-differences-across-plans.md
Vida 34a96690c1 vida: directed research — Medicare Advantage, senior care, international comparisons (#184)
Co-authored-by: Vida <vida@agents.livingip.xyz>
Co-committed-by: Vida <vida@agents.livingip.xyz>
2026-03-10 19:45:43 +00:00

3.8 KiB

type title author url date domain secondary_domains format status priority tags
source Improving Medicare Advantage by Accounting for Large Differences in Upcoding Across Plans USC Schaeffer Center / Health Affairs Forefront https://schaeffer.usc.edu/research/improving-medicare-advantage-by-accounting-for-large-differences-in-upcoding-across-plans/ 2025-02-03 health
paper unprocessed high
medicare-advantage
upcoding
risk-adjustment
coding-intensity
market-dynamics
plan-variation

Content

Key Findings

  • CMS overpaid MA by $50 billion (13%) in 2024 due to upcoding
  • 15-percentage-point variation in coding intensity among 8 largest MAOs
  • 10 MAOs have coding intensity more than 20% higher than traditional Medicare levels

The Competitive Dynamics of Upcoding

  • Aggressive upcoding permits MA plans to offer better benefits than either TM or less-aggressive MA plans
  • Enhanced benefits attract additional enrollees → both higher profits per enrollee AND increased market share
  • This creates a perverse competitive advantage: the more you upcode, the more you grow
  • Plans that code accurately are at a competitive DISADVANTAGE

The Virtuous/Vicious Cycle

  1. Plan upcodes aggressively → receives higher payments
  2. Higher payments fund better supplemental benefits (dental, vision, $0 premiums)
  3. Better benefits attract more enrollees
  4. More enrollees → more revenue → more resources for upcoding
  5. Competitors must either match upcoding or lose market share

Policy Recommendations

  • Implement MedPAC recommendations for risk score calculation reform
  • Exclude diagnoses from health risk assessments (in-home visits)
  • Use two years' claims data for risk score calculation
  • Plan-level coding intensity adjustment (not just system-wide 5.9%)
  • MA enrolls lower-spending people → large overpayments (favorable selection, June 2023)
  • Favorable selection ups the ante on MA payment reform (June 2023)
  • MedPAC critics get it wrong on overpayment estimates (July 2024)

Agent Notes

Why this matters: This research reveals the most structurally damaging aspect of MA upcoding: it's not just waste, it's a competitive advantage mechanism. Plans that upcode more grow faster because they can offer better benefits. This creates a race to the bottom where accurate coding is penalized by the market. The 15-percentage-point variation among top 8 MAOs shows this isn't uniform — some plans are far more aggressive than others. What surprised me: The competitive dynamics framing. I'd thought of upcoding as fraud/gaming. But USC Schaeffer frames it as a market mechanism: upcoding creates a competitive advantage that compounds. Honest plans can't compete. This is a textbook case of adverse selection — but among plans, not patients. KB connections: proxy inertia is the most reliable predictor of incumbent failure because current profitability rationally discourages pursuit of viable futures, Devoted is the fastest-growing MA plan at 121 percent growth because purpose-built technology outperforms acquisition-based vertical integration during CMS tightening Extraction hints: Claim about upcoding as competitive advantage mechanism — plans that code accurately are at a structural disadvantage, creating a race to the bottom in coding integrity.

Curator Notes

PRIMARY CONNECTION: CMS 2027 chart review exclusion targets vertical integration profit arbitrage by removing upcoded diagnoses from MA risk scoring WHY ARCHIVED: The competitive dynamics framing adds a dimension the KB doesn't have — it's not just about how much upcoding costs, but how upcoding shapes market structure. EXTRACTION HINT: The "honest plans can't compete" insight is the most extractable claim. It connects upcoding to market concentration (UHG/Humana duopoly).